



30/05/2013 20.06.37

Primo autore

PASINI FELICE (Medico)
ONCOLOGIA, OSPEDALE SANTA MARIA DELLA MISERICORDIA - ROVIGO
felicepasini@excite.com
Non sono socio AIOM
Socio presentatore: INNO ALESSANDRO

Area tematica

Genitourinary tumors

Titolo

Targeted therapies (TT) for metastatic renal cell carcinoma (mRCC) in the real world setting: an Italian multicentric survey of 1120 pts.

Testo

Background: this survey was aimed to evaluate the outcome of TT in mRCC pts in the community setting.

Methods: individual data of 1120 pts treated with TT from mid 2007 to December 2012 in 30 Institutions were reviewed.

Results: Median follow up was 16 mo (range 1-85), median age 65 yrs (range 23-90), histology was clear cell in 78% and nephrectomy was performed in 88% of the cases. Main metastatic sites were lung (63%), lymph nodes (40%), bone (31%), liver (20%). Overall survival (OS) was 69%, 50%, 36%, 27%, 19% at 1, 2, 3, 4, 5 yrs, respectively, without difference in relation to the number of pts treated per center (median 37, range 6-98).

1stline tx was Sunitinib (SU) in 869 pts (77%), sorafenib (SO) in 142 (12.5%), temsirolimus in 46 (4%), others (6.5%). Median PFS of 1stline (mPFS1) SU was 10.7 mo and that of SO 7.9 mo (p=0.004). Dose reduction of SU and SO was required in 48% and 39% of the cycles, respectively; 269 pts (24%) received ≤ 2 cycles of SU/SO mostly for rapid progression and/or deterioration and had a mOS of 5 mo.

2ndline tx was performed in 48% of the pts: SO 186 (17%), everolimus (EV) 149 (13%), SU 126 (11%), temsirolimus 26 (2.3%), chemo-immunotherapy 33 (3%), others 1.4%. mPFS2 was 6.9 mo for SU, 4.7 mo for SO, 4.0 for EV; SU vs SO p=0.018, SU vs EV p=0.008.

219 pts (19.5%) received 3 lines of tx: VEGFi-VEGFi-mTORi (A) 85 pts (39%), VEGFi -mTORi-VEGFi (B) 65 pts (30%), VEGFi-VEGFi- VEGFi (C) 27 pts (12%), others (various schedules of chemo/immunotherapy) 42 pts (19%) (D). mOS of the group was 40 mo: 45 (A), 39 (B), 45 (C), 35 (D), respectively; A vs B p= 0.4, A vs D p=0.009.

Presently, 1stline tx is ongoing in 167 pts (15%) (median duration 18 mo, range 2-71), 2nd line tx in 67 pts (6%). About 5% of the pts survived at least 12 mo after stopping TT (median time from end of TT 50 mo, range 13-61). 210 pts (19%) died within 30 days after the last dose of tx.

Conclusions: i) In the community setting PFS and OS reproduced data of clinical trials; ii) no variation according to center volume was found showing a widespread expertise; iii) about 40% of pts became long survivors, mostly after subsequent lines of tx and 5% even after stopping tx; iv) 24% of pts were refractory to tx; v) 19% of pts died within 1 mo after stopping tx; vi) further studies are needed to better identify the different subsets of pts in order to improve the efficacy of TT.

Parole Chiave

1. renal
2. survey

Co-autori

1. **FRACCON ANNA PAOLA** (Medico - Età uguale o inferiore a 40 anni)
ONCOLOGIA, CASA DI CURA DOTT. PEDERZOLI - PESCHIERA DEL GARDA
2. **INNO ALESSANDRO** (Medico - Età uguale o inferiore a 40 anni)
ONCOLOGIA, OSPEDALE SANTA MARIA DELLA MISERICORDIA - ROVIGO
3. **BASSO UMBERTO** (Medico)
ONCOLOGIA 1, IOV - PADOVA
4. **MASSARI FRANCESCO** (Medico - Età uguale o inferiore a 40 anni)
ONCOLOGIA, AOUI dU - VERONA
5. **MACRINI SVEVA** (Medico - Età uguale o inferiore a 40 anni)
ONCOLOGIA - UDINE
6. **VALCAMONICO FRANCESCA** (Medico - Età uguale o inferiore a 40 anni)
ONCOLOGIA, SPEDALI CIVILI - BRESCIA
7. **LO RE GIOVANNI** (Medico)
ONCOLOGIA - PORDENONE
8. **VATTEMI EMANUELA** (Medico - Età uguale o inferiore a 40 anni)
ONCOLOGIA - BOLZANO
9. **DURANTE EMILIA** (Medico)
ONCOLOGIA, OSPEDALE MATER SALUTIS - LEGNAGO
10. **SORARU' MARIELLA** (Medico)
ONCOLOGIA - CAMPOSAMPIERO
11. **BEARZ ALESSANDRA** (Medico)
ONCOLOGIA, CRO - AVIANO
12. **SARTORI DONATA** (Medico)
ONCOLOGIA - MIRA-DOLO
13. **BERTOCCHI PAOLA** (Medico - Età uguale o inferiore a 40 anni)
ONCOLOGIA POLIAMBULANZA - BRESCIA
14. **PEGORARO CRISTINA** (Medico - Età uguale o inferiore a 40 anni)
ONCOLOGIA - MONTECCHIO MAGGIORE
15. **SALVAGNO LUIGI** (Medico)
ONCOLOGIA - VITTORIO VENETO

16. **GIUSTO MAURO** (Medico)
ONCOLOGIA - BELLUNO
17. **SEGATI ROMANA** (Medico)
ONCOLOGIA - FELTRE
18. **MEDICI MICHELE** (Medico)
ONCOLOGIA - MESTRE
19. **CREPALDI GIORGIO** (Medico)
ONCOLOGIA, OSPEDALE SANTA MARIA DELLA MISERICORDIA - ROVIGO
20. **BARILE CARMEN** (Medico)
ONCOLOGIA, OSPEDALE SANTA MARIA DELLA MISERICORDIA - ROVIGO